Side effects include:
Children  years of age receiving oral solution: Diarrhea, epistaxis, pharyngitis, flu-like symptoms, fatigue, stomatitis, tooth disorder, earache, viral infection, rash.
Children  years of age receiving oral solution: Nervousness, wheezing, fatigue, hyperkinesia, abdominal pain, conjunctivitis, dysphonia, upper respiratory tract infection.
Adults and children  years of age receiving conventional or orally disintegrating tablets: Headache, somnolence, fatigue, dry mouth.
Fixed combination loratadine (the active ingredient contained in Tavist ND) pseudoephedrine sulfate preparations: Insomnia, dry mouth, headache, somnolence, nervousness, dizziness, fatigue.

The most commonly reported side effects included headache, somnolence nervousness, and fatigue.
Very common ( or more): Headache (up to )Common ( to ): Sedation/somnolenceVery rare (less than ): Dizziness, convulsionFrequency not reported: Syncope, paresthesia
Common ( to ): NervousnessUncommon ( to ): InsomniaFrequency not reported: Depression, paroniria
Common ( to ): FatigueFrequency not reported: Fever, viral infection, tinnitus, malaise
Common ( to ): Dry mouthVery rare (less than ): Nausea, gastritisFrequency not reported: Dyspepsia, diarrhea, constipation, abdominal/gastric pain, altered taste, increased saliva
Uncommon ( to ): Increased appetite
Very rare (less than ): Angioedema, rash, alopeciaFrequency not reported: Pruritus, rash on face
Frequency not reported: Increased frequency of urination, urine discoloration, menstruation delay
Very rare (less than ): Tachycardia, palpitationFrequency not reported: Hypertension, hypotension, chest pain
Very rare (less than ): Hypersensitivity reactions, anaphylaxis
Very rare (less than ): Abnormal hepatic function
Frequency not reported: Epistaxis, nasal dryness, pharyngitis, coughing
Frequency not reported: Myalgia
It is possible that some side effects of Tavist ND may not have been reported.
These can be reported to the FDA here.
Always consult a healthcare professional for medical advice.